AHRQ poses questions on VTE prophylaxis
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research and Quality is taking comments through June 4 on the comparative effectiveness of venous thromboembolism (VTE) prophylaxis in orthopedic surgery. Key questions posted online May 7 address the overall baseline risk of VTE and bleeding outcomes in patients undergoing major orthopedic surgery such as total hip or knee replacement or hip fracture surgery. AHRQ also plans to look at what patient characteristics can predict or differentiate risk of VTE and bleeding, whether risk can be detected by venography or ultrasound, and how preventive treatments impact patient outcomes
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.